Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crisdesalazine - GNT Pharma

Drug Profile

Crisdesalazine - GNT Pharma

Alternative Names: AAD-2004

Latest Information Update: 21 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurotech Pharmaceuticals
  • Developer AmKor Pharma; GNT Pharma
  • Class Anti-inflammatories; Antidementias; Antiparkinsonians; Salicylates; Small molecules; Sulfonamides
  • Mechanism of Action Amyloid beta-protein inhibitors; Antioxidants; Dinoprostone antagonists; Free radical scavengers; Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Amyotrophic lateral sclerosis; Depressive disorders; Parkinson's disease
  • Preclinical Pain
  • Discontinued Arthritis; Diabetes mellitus; Pancreatitis

Most Recent Events

  • 21 Apr 2020 Phase I development for Amyotrophic lateral sclerosis is still ongoing in South Korea (GNT Pharma pipeline, April 2020)
  • 21 Apr 2020 Phase I development for Depressive disorders is still ongoing in South Korea (GNT Pharma pipeline, April 2020)
  • 21 Apr 2020 Phase I development for Parkinson's disease is still ongoing in South Korea (GNT Pharma pipeline, April 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top